Spatial Concept – Page 14

Ono Pharmaceutical Strengthens Oncology Portfolio with Acquisition of Deciphera Pharmaceuticals for $2.4 Billion

1 year ago talkbio0Tagged Acquisition (action), cancer treatments, Clinical Development, Collaboration, Deciphera, Dosage Forms, expansion, Generalized, Market, Oncology Pipeline, strategic

Ono Pharmaceutical, Deciphera Pharmaceuticals, oncology pipeline, acquisition, $2.4 billion, cancer treatments, kinase inhibitors, strategic expansion, global market, clinical development, collaboration.

Bristol Myers and Cellares Collaborate on Global CAR-T Manufacturing Deal

2 years ago talkbio0Tagged Biopharma, CAR-T, Cellares, diversification, Generalized, Manufacture, Myers, Partner in relationship

Bristol Myers, Cellares, CAR-T, biopharma, manufacturing partners, diversification, global deal

Shimadzu Corporation Expands US Presence with Three New R&D Centers for Pharmaceutical Growth

2 years ago talkbio0Tagged business growth, Central, Corporation, Drug Industry, expansion, innovation, Shimadzu, Technology, U.S.

Shimadzu Corporation, R&D centers, US expansion, pharmaceutical industry, business growth, innovation, technology.

FDA Approves Takeda’s Subcutaneous Entyvio Injection for Maintenance Therapy in Moderate to Severe Crohn’s Disease

2 years ago talkbio0Tagged Crohn 's disease, Entyvio, Injection of therapeutic agent, Maintenance therapy, subcutaneous, Takeda, United States Food and Drug Administration

FDA, Takeda, Entyvio, Subcutaneous, Injection, Maintenance Therapy, Crohn’s Disease

Sanofi Restructures US Commercial Vaccine Group Amid Cost-Saving Campaign

2 years ago talkbio0Tagged Commercial Vaccine, Cost-Savings Campaign, Effectiveness, Efficiency, Employee, Evolving, Market, Optimization, Outplacement, restructuring, sanofi, streamlined strategic sales, Structure, Vaccines

Sanofi, Restructuring, US Commercial Vaccine Group, Cost-Savings Campaign, Streamlined Strategic Sales Structure, Evolving Vaccine Market, Optimization for Efficiency and Effectiveness, Employee Support and Outplacement Assistance

Biopharma Layoff Tracker 2024: Sanofi, Vedanta, Fujifilm, and More Companies Reduce Workforce

2 years ago talkbio0Tagged Acorda, Biological Factors, Biopharma layoffs, Cara, Eiger, Fujifilm, Genomic Orientation, Invitae, Pfizer, sanofi, Vedanta

Biopharma layoffs, Sanofi, Vedanta, Fujifilm, Acorda Therapeutics, Eiger BioPharmaceuticals, Invitae, Sientra, Strand Therapeutics, Cara Therapeutics, Pfizer

CMS to Increase Reimbursement for New Sickle Cell Gene Therapies through Outcomes-Based Agreements

2 years ago talkbio0Tagged Administrative action, Burden, Casgevy, Cells, Centers for Medicaid and Medicare (CMS) Pnl, Central, CGT, Equitable Access, Fertility, Grail, Increased, Lyfgenia, Medicaid Access, Medicare & Medicaid Services, OBAs, Outcomes-Based Agreements, Reimbursement, sickle cell gene therapies

CMS (Centers for Medicare & Medicaid Services), Sickle Cell Gene Therapies, Increased Reimbursement, Outcomes-Based Agreements (OBAs), Cell and Gene Therapy (CGT) Access Model, Medicaid Access, Casgevy, Lyfgenia, Fertility Preservation Services, Equitable Access, Administrative Burden Reduction

The Transformative Future of Specialist Distribution: Adaptive Strategies and Technological Innovations

2 years ago talkbio0Tagged **Last-Mile Solutions**:, Adaptive Strategies, Artificial Intelligence, Automation, Data Integration, Global Expansion, Hospital specialist, Smart Distribution Centers, Spatial Distribution, Technological Innovations, trends qualifier, Virtual Distribution

Specialist Distribution, Future Trends, Adaptive Strategies, Technological Innovations, Automation, Artificial Intelligence, Last-Mile Solutions, Virtual Distribution, Data Integration, Global Expansion, Smart Distribution Centers

Diagonal Therapeutics Secures $128 Million Series A Funding through Innovative Antibody Agonists

2 years ago talkbio0Tagged Antibody agonism, Cells, Diagonal, Funding, Rare Diseases, switches

Diagonal Therapeutics, Series A funding, Antibody agonism, Cellular “on” switches, Rare diseases

Diagonal Therapeutics Secures $128 Million Funding to Target Rare Diseases

2 years ago talkbio0Tagged Antibodies, Blue-chip, Chronic anemia, Diagonal, Merck's, Orphan disease treatment, Rare diseases focus, research, Winrevair

Diagonal Therapeutics, Antibody biotech, $128 million funding, Rare diseases focus, Orphan disease treatment, Chronic anemia, Merck’s Winrevair related research, Blue-chip investors